Interventional cardiology is currently in major focus in all cardiology meetings and seminars. Not all patients are candidates for this invasive procedure. This is well studied with multiple clinical trials. A country like India with vast rural areas and population many are afraid or not able to access the super-specialty interventional care. Emerging treatments like Enhanced External Counter pulsation (EECP), which is a non-invasive day care procedure, safe and effective method to promote angiogenesis should be brought to the attention of patients, general physicians, and policymakers. This technology is very effective to help many patients to improve the quality of life without having to undergo elective Percutaneous coronary angioplasty (PTCA) or coronary artery bypass surgery (CABG).

Currently, the United States Food and Drug Administration (US FDA) cleared EECP as a Class II device for the treatment of refractory angina pectoris, and all other diseases including myocardial infarction, cardiogenic shock, and congestive heart failure as Class III device. The Centers for Medicare and Medicaid Services (CMS) in the US also approved EECP for national reimbursement coverage for the treatment of refractory angina patients in 2000